Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting

Autor:	Jingyi Yang, Hao Guo, Lu Han, Yongping Song, Keshu Zhou
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Chimeric antigen receptor Dual-targeted Hematological malignancy Clinical trial Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-4 (2024)
Druh dokumentu:	article
ISSN:	2162-3619
DOI:	10.1186/s40164-024-00485-8
Popis:	Abstract Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/4751ec16a45d402d9601992b5e44c432 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.